Beyond Air, Inc. (XAIR) NASDAQ
0.47
-0.0162(-3.33%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.47
-0.0162(-3.33%)
Currency In USD
| Previous Close | 0.49 |
| Open | 0.49 |
| Day High | 0.49 |
| Day Low | 0.47 |
| 52-Week High | 5.84 |
| 52-Week Low | 0.38 |
| Volume | 149,696 |
| Average Volume | 303,323 |
| Market Cap | 2.38M |
| PE | -0.11 |
| EPS | -4.47 |
| Moving Average 50 Days | 0.57 |
| Moving Average 200 Days | 1.33 |
| Change | -0.02 |
Beyond Air to Participate in the 38th Annual Roth Conference in March
GlobeNewswire Inc.
Mar 11, 2026 11:00 AM GMT
GARDEN CITY, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve th
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.
GlobeNewswire Inc.
Mar 10, 2026 11:30 AM GMT
GARDEN CITY, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve t
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections
GlobeNewswire Inc.
Feb 20, 2026 1:00 PM GMT
GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve th